1West J,Fagan K,Steudel W.Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle.Circulation Research,2004,94(2):09-11.
2Teichert-Kuliszewska K,Kutryk Michael JB,Kuliszewski Michael A.Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival.Circulation Research,2006,98(4):209.
3Long Lu,MacLean Margaret R,Jeffery Trina K.Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice.Circulation Research,2006,98 (2):818.
4Marcos E,Fadel E,Sanchez O,et al.Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension.Circ Res,2004,94(9):1 263-1 270.
6Christou HA,Yoshida V.Increase vascular endothelial growth factor production in the lungs of rats with hpoxia-induced pulmonary hypertention.Am Respir Cell Mol Biol,1998,18:768-776.
7Tuder BM,Flook BE.Incrcreased gene expression for vasculoar endothelial growth factor(VEGF) and VEGF receptors KDB/FLkand Flt in lungs exposed to acute or to clwonid hypoxia.Clin Invest,1995,95:1 798-1 807.
9Oka M,Homma N,Taraseviciene-Stewart L.Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.Circulation Research,2007,100:923.
10Fernandez Paltron C,Radomski M,Davidge S.Vascular matyix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor.Circ Res,1999,85:906-911.
二级参考文献71
1Janssen B,Rindermann M,Barth U,et al.Linkage analysis in a large family with PPH:genetic heterogeneity and a second PPH Locus on 2 q31-32.Chest,2002,121(Suppl):54S-56S.
2Christman BW,McPherson CD,Newman JH,et al.An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.N Engl J Med,1992,327:70-75.
3Hoshikawa Y,Voelkel NF,Gesell TL,et al.Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling.Am J Respir Crit Care Med,2001,164:314-318.
4Tuder RM,Cool CD,Geraci MW,et al.Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension.Am J Respir Crit Care Med,1999,159:1925-1932.
5Voelkel NF,Tuder RM,Wade K,et al.Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.J Clin Invest,1996,97:2491-2498.
6Massague J,Blain SW,Lo RS.TGF- signalling in growth control,cancer,and heritable disorders.Cell,2000,103:295-309.
8Wright L,Tuder RM,Wang J,et al.5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension.Am J Respir Crit Care Med,1998,157:219-229.
9Simmoneau G,Barst R,Galie N,et al.Continuous subcutaneous infusion of treprostinil,a prostacyclin analogue,in patients with pulmonary arterial hypertension.Am J Respit Crit Care Med,2002,165:800-804.
10Fruhwald FM,Kjellstrom B,Perthold W,et al.Continuous hemodynamic monitoring in pulmonary hypertensive patients treated with inhaled iloprost.Chest,2003,124:351-359.
